Outcome and follow-up
The patient was diagnosed with a MSSA subcapsular splenic abscess and
associated empyema, in the context of being immunosuppressed and
recently commencing tocilizumab. Following the identification of MSSA,
the patient was changed from empirical antibiotic treatment with
intravenous amoxicillin-clavulanic acid to intravenous flucloxacillin
monotherapy. There was subsequently a good biochemical and clinical
response with normalisation of neutrophilia and a slow downtrend in the
CRP to 27 mg/L, after three weeks of intravenous antibiotic therapy and
source control with splenic abscess drainage and VATS washout. She was
discharged home on oral flucloxacillin monotherapy to complete a
four-week total course of antibiotic therapy and made a full recovery.
Tocilizumab was ceased, and leflunomide and methotrexate were withheld
on discharge in the context of infection, with ongoing follow-up planned
with her rheumatologist.